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INTRODUCTION 
 
 Bronchial asthma is one of the most common diseases affecting nearly 300 
million people globally (i.e.,) 8-10 % of the population. The rising prevalence of 
bronchial asthma in developing nations like India is attributed to various factors 
like urbanization, environmental pollution, industrialization, lifestyle changes.(1) 
 
Bronchial asthma is a chronic inflammatory disease of the airways 
characterized by airway hyperresponsiveness and airflow obstruction that is often 
reversible at least in the initial stages.(2) The pathogenesis of asthma is very 
complex and is not fully elucidated yet.  A variety of cells and inflammatory 
mediators play a critical role in initiating, perpetuating and coordinating the 
repeated cycles of inflammation. The fundamental pathology in asthma is the 
exaggerated TH2 response to normally harmless environmental antigens resulting 
the release of TH2 cytokines mainly interleukins 4,5 and 13 of which IL4 and IL 
13 are responsible for the production of antigen specific IgE by B lymphocytes. IL 
5 is responsible for prolonging the survival of eosinophils.(2,3) 
 
The repeated cycles of inflammation lead to infiltration of airways with 
eosinophils, lymphocytes and elaboration of various interleukins, chemokines and 
growth factors. These inflammatory agents cause various changes which are 
collectively termed as airway remodelling such as hypertrophy and hyperplasia of 
bronchial smooth muscle cells, epithelial injury, mucus gland hyperplasia, 
deposition of sub epithelial collagen, fibrosis and increased vascularity resulting 
in partly reversible or irreversible airflow obstruction. (2,3) 
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Treatment of bronchial asthma involves two major class of medications 
viz, bronchodilators and anti-inflammatory agents. Bronchodilators includes beta 
2 agonists, anticholinergics and methylxanthines. These are mainly used as 
reliver(rescue) medications. These agents act principally by relaxation of 
bronchial smooth muscle and thereby reversing the airflow obstruction. Anti-
inflammatory agents include corticosteroids, leukotriene antagonists and anti IgE 
therapy. These are mainly used as chronic controllers. These agents reduce airway 
inflammation and help to maintain control over asthma.(4,5) However, the chronic 
use of corticosteroids is associated with various adverse effects both locally and 
systemically like dysphonia, oral candidiasis, weight gain, osteoporosis, 
hypertension, etc and there is a variability in patient’s response to 
corticosteroids(4) Given this situation there is a need for investigating the role of 
new drugs in the treatment of bronchial asthma. Of the various new therapies 
cholecalciferol has been found to have a role in the treatment of bronchial asthma. 
 
  Cholecalciferol or vitamin D, a fat-soluble vitamin is a prohormone with 
several active metabolites that act as hormones. Cholecalciferol is synthesized in 
our body from 7- dehydrocholesterol by the action of sunlight (UV B rays). 
Cholecalciferol so formed does not have significant biological activity, it must be 
converted to its metabolically active form 1,25 dihydroxycholecalciferol or 
calcitriol by series of hydroxylation reactions occurring sequentially in liver and 
kidney.(6) 
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 1,25 dihydroxycholecalciferol acts by binding to its intracellular receptor, 
the vitamin D receptor resulting in the translocation of Vitamin D Receptor 
complex to nucleus and binding to specific sequences of DNA called Vitamin D 
Responsive Elements leading to changes in the transcription and subsequent 
translation of various proteins. The major roles of cholecalciferol in our body are 
promoting intestinal calcium and phosphate absorption, increasing renal 
reabsorption of calcium and phosphate and bone modelling and remodelling. 
Cholecalciferol is also found to have various effects in addition to calcium 
homeostasis like in immune system, skin, skeletal muscles, etc.(6) 
 
 Several studies have shown a relationship between serum vitamin D levels 
and bronchial asthma.(7,8) Low levels of Vitamin D are associated with reduced 
lung function, frequent exacerbations and severe disease.  In addition, vitamin D 
deficiency is more common in asthmatics compared to general population as 
asthmatic patients tend to spend more time in doors, are less active physically and 
therefore their exposure to sunlight is less.(7)   
 
Vitamin D is found to have anti-inflammatory activity in several in vitro 
studies.  Vitamin D reduces inflammation by decreasing the levels of 
proinflammatory cytokines and increasing the levels of anti-inflammatory 
cytokines like interleukin 10.(9)   Vitamin D also reduces bronchial smooth muscle 
cell hypertrophy and hyperplasia.  In addition, vitamin D improves response to 
inhaled and oral corticosteroids.(10) Thus, Vitamin D by inhibiting the repeated 
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cycles of chronic inflammation reduces airway remodelling which is the major 
pathologic change seen in the lungs of asthmatic patients.(7) 
 
Based on the anti-inflammatory and immunomodulatory effects of 
cholecalciferol, this study was taken up to evaluate the efficacy and safety of 
Cholecalciferol in patients with bronchial asthma in our community.  
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
INTRODUCTION 
Asthma is a chronic inflammatory disease of the airways characterized by 
airway obstruction, which is often reversible. Asthma is not a single disease but 
rather a clinical syndrome and a heterogenous disease. Asthma typically shows 
multiple endotypes with common manifestations but has distinct pathophysiologic 
mechanism and aetiology. This heterogeneity is seen as variability in pathologic, 
clinical and physiologic parameters between different patients.(2) 
 
HISTORY OF ASTHMA 
The term Asthma is derived from the Greek word aazein, which means to 
exhale with the open mouth.(11)  
 
The earliest text where the word asthma is found is The Corpus 
Hippocraticum, by Hippocrates. Aretaeus (100 AD), a Greek physician, wrote the 
first clinical description of asthma. Galen (200 AD), another Greek physician, 
wrote several texts on asthma describing the clinical manifestations and 
treatment.(11) 
 
Van Helmont (16th century), a Belgian physician and chemist, was the first 
one to propose that asthma originates in the lungs. Bernardino Ramazzini (17th 
century), an Italian clinician hypothesized a link between asthma and organic dust 
and exercise.(11) 
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Bronchodilators were used in the treatment of asthma as early as the 
beginning of 19th century. However, the role of inflammation in asthma was 
recognized only in the 1960s leading to the development and use of anti-
inflammatory medications.(11) 
 
EPIDEMIOLOGY 
Bronchial asthma is one of the most common disease worldwide affecting 
nearly 300 million people (8-10% of population). The prevalence of asthma is 
increasing rapidly in developing countries such as India due to factors such as 
increasing urbanization, industrialization, air pollution.(1,12) 
 
Peak age of presentations of asthma is 3 years although asthma can present 
at any age. In children, males are more affected than females. In adults, the sex 
difference is not significant. Usually the severity of asthma is constant and does 
not vary significantly in a patient. Usually patients who develop asthma at an 
early age become asymptomatic during adolescence, but asthma can return at a 
later age in these patients. However, patients who become asthmatic at a later age 
have a persistent disease and they rarely become asymptomatic.(1) 
 
Bronchial asthma is a disease with severe morbidity however death due to 
asthma is uncommon. Risk factors for death are poorly controlled patients, lack or 
poor compliance to therapy, previous admission with near fatal asthmatic attack.(1) 
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RISK FACTORS 
 Asthma shows an interplay between various genetic and environmental 
factor.(1) 
 
ENDOGENOUS FACTORS 
1. ATOPY 
This is the most significant risk factor. Atopy refers to the exaggerated IgE 
mediated immune response to various allergens. 
 
Common allergens are house dust mites, cat and dog fur, cockroach, pollen 
and fungi. Asthmatic patients have significantly higher prevalence of other 
allergic diseases like allergic rhinitis, allergic conjunction and atopic dermatitis.(1) 
 
2.GENETIC FACTORS 
Several genes are implicated in the pathogenesis of asthma like genes 
involved in cytokine productions especially chromosome 5q containing genes for 
IL-4, IL-5, IL-9, IL-13. Other genes implicated in the pathogenesis are ADAM 
33, DPP 10, HLA-G, ORMDL-3.(1) 
 
3.AIRWAY HYPERRESPONSIVENESS 
It is the characteristic physiologic abnormality seen in asthmatics. Airway 
hyperresponsiveness refers to the excess bronchoconstrictor response to various 
agents that normally would not have significant effect on airways. This antecedes 
the development of asthma. Presence of airway hyperresponsiveness increases the 
risk of developing asthma.(1) 
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ENVIRONMENTAL FACTORS 
1. Infection 
Viral infections like respiratory syncytial virus, rhino virus, atypical 
bacterial infections like chlamydia, mycoplasma increase the risk of asthma as 
well as they trigger acute attacks. 
 
Hygiene hypothesis and asthma- Lack of infectious stimuli in early 
childhood preserves the T-Helper 2 response which predisposes to asthma 
whereas exposure to various infectious agents causes a shift to protective TH1 
response. This is called hygiene hypothesis which may also contribute to the 
development of asthma.(1) 
 
2. Air pollution 
 Especially gases like ozone, sulphur dioxide, various components of motor 
vehicle exhaust increase the risk of developing asthma.(1) 
 
3. Occupation 
 Occupational asthma is asthma occurring de novo as a consequence of 
exposure to specific agents in persons without previous history of asthma. It is of 
two types. 
 Sensitizer induced asthma 
 Irritant induced asthma (2) 
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Causes of Occupational Asthma 
Sensitizing Agent-Induced Asthma (2) 
Agent Workers at Risk 
Acrylate Dental workers; adhesive handlers 
Anhydrides Workers using epoxy resin for plastics 
Animal protein allergens Veterinary workers; animal handlers 
Dyes Textile workers 
Enzymes Pharmaceutical workers; bakery workers; laboratory workers 
Formaldehyde, 
glutaraldehyde Hospital and healthcare workers 
Isocyanates Installers of insulation; manufacturers of plastics; rubbers and foam; spray painters 
Latex Healthcare workers; rubber workers 
Persulfate Hairdressers 
Wood dusts Forestry workers; sawmill workers; carpenters 
 
Common Agents Responsible for Irritant-Induced Asthma(2) 
 Acids (acetic, hydrochloric, sulfuric) 
 Alkaline dust 
 Ammonia 
 Bleach 
 Chlorine 
 Diesel exhaust 
 Formalin 
 Mustard 
 Oxide (calcium) 
 Paints  
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Occupational asthma accounts for 10% of the asthmatics. Patient typically 
becomes symptomatic during working week and improves during weekend or 
vacation. 
 
Early detection and avoidance of further exposure to etiologic agent is 
critical in occupational asthma. 
 
4.Obesity 
 Obesity increases the risk of asthma by reducing tidal volume and 
functional residual capacity; increasing gastroesophageal reflux and increasing the 
expression of proinflammatory cytokines IL-6 and TNF-α by adipocytes. 
 
5. Low birth weight 
6. Prematurity 
7. Duration of breast feeding 
8. Diet(1) 
 
PRECIPITANTS OF BRONCHIAL ASTHMA 
These agents trigger bronchoconstriction and inflammation 
1. Allergens such as pollen, animal fur cause activation of mast cells resulting 
in degranulation and release of inflammatory mediators. 
2. Viral infections such as respiratory syncytial virus, rhino virus, corona 
virus. 
3. Drugs such as beta blockers by increasing cholinergic mediated 
bronchoconstriction; aspirin by inhibiting cyclooxygenase it decreases the 
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level of prostaglandin E2 which has a protective effect in asthma by 
increasing the synthesis of proinflammatory leukotriene B4, C4, D4, E4.(3) 
4. Exercise leads to hyperventilation which increases the osmolality in 
bronchus triggering the release of inflammatory mediators. 
5. Air pollution 
6. Occupation – Exposure to fumes containing epoxy resins, plastics, organic 
dust such as cotton, wood, gases like toluene, chemicals such as 
formaldehyde, biological agents such as penicillin products.(3) 
7. Physiological stress 
8. Gastroesophageal reflux disease 
9. Foods containing additives such as metabisulfite extrusion 
10. Tobacco smoking(1) 
 
Risk Factors and Triggers Involved in Asthma(2) 
Endogenous Factors Environmental Factors Triggers 
Atopy Allergens–indoor 
Allergens (especially 
house dust mite, animal 
dander, cockroach, fungi, 
seasonal pollens) 
Airway 
hyperresponsiveness 
Allergens– outdoor 
(fungi, pollens) 
Changes in the weather 
(cold air) 
Ethnicity Obesity Drugs (aspirin, β-blockers, NSAIDs) 
Gender Occupational sensitizers 
Exercise and 
hyperventilation 
Genetic predisposition 
Parasitic infections 
Extreme emotional 
expression (laughing, 
stress) 
Respiratory infections 
(viral) 
Irritants (household 
sprays, paint fumes) 
Socioeconomic status Respiratory infections 
Tobacco smoking (active 
and passive) 
Sulfur dioxide and other 
pollutant gases 
Tobacco smoking 
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TYPES OF BRONCHIAL ASTHMA 
1.Atopic 
 Most common type. 
 Due to IgE mediated type I hypersensitivity reaction. 
 Usually begins in childhood. 
 Asthmatic attacks are triggered by inhalation of environmental 
allergens such as dust, pollen. 
 Family history of atopy is present. 
 Serum total IgE levels are increased. 
 Skin test for allergens in positive.(3) 
 
2.Non-Atopic 
 No evidence of allergen sensitization. 
 Seen in adults. 
 Family history is usually negative. 
 Air pollution and viral infection are the common precipitants. 
 Triggers leading to asthmatic attacks. 
 Skin tests for allergens is negative.(3) 
 
PATHOGENESIS OF ASTHMA 
 The pathogenesis of asthma is very complex and is not fully understood. 
This involves a variety of cells and inflammatory mediators that are activated by 
several mechanisms. The resulting airway inflammation is central to the 
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pathophysiology of bronchial asthma and causes bronchial dysfunction partly 
through changes caused by the release of inflammatory mediators and partly by 
airway remodelling. The fundamental abnormality in asthma is exaggerated T-
Helper 2(TH2) response to normally harmless environmental antigens. Since the 
pathogenesis of asthma involves both acute and chronic inflammation it is prudent 
to discuss these in detail.(2,3,13) 
 
EFFECT OF ACUTE INFLAMMATION 
 When an antigen enters the airway of a susceptible person for the first time, 
it is taken up by the dendritic cells which then travel to pulmonary lymph nodes 
where the antigen is presented to naïve CD4 T cells. Dendritic cells play a key 
role in determining the differentiation of CD4 T cell. Prior to this, dendritic cells 
are influenced by molecular signals from bronchial epithelial cells and other local 
cells.(2) 
 
In genetically predisposed persons, TSLP (Thymic Stromal Lympho 
Protein) and GM-CSF (Granulocyte Monocyte Colony Stimulating Factor) 
produced by bronchial epithelium influence the dendritic cell to promote the 
differentiation of CD4 T cells to T-Helper2 lineage which eventually sets up the 
stage for allergic inflammation.(2) 
 
These T-Helper2 cells on reaching the airways secrete TH2 chiefly IL-4, IL-
15, IL-13 which play a key role in establishing the framework for further 
inflammation. These cytokines act on other inflammatory cells leading to self-
fuelling cycles of inflammation and cellular injury. IL-4 promotes IgE production, 
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IL-5 causes activation of eosinophils and IL-13 causes mucus hypersecretion and 
also promotes IgE production.(2) 
 
These antigen specific IgE binds to IgE receptor on the surface of mast 
cells. During subsequent exposure with sensitizing allergen, antigen-antibody 
reaction results in cross linking of IgE receptor on mast cells resulting in the 
release of variety of inflammatory mediators like histamine, leukotriene, 
prostaglandin, proteases which cause bronchoconstriction, plasma leakage, airway 
edema and increased mucous secretion. This is early phase of acute inflammation. 
Mast cells also release chemo attractants such as leukotrienes, chemokines, IL-5 
which recruit a variety of inflammatory cells like eosinophils, basophils, 
neutrophils, lymphocytes. This forms the late phase of acute inflammation.(2) 
 
PATHOGENESIS OF ASTHMA 
 
15 
 
 
INFLAMMATORY MEDIATORS 
They initiate, perpetuate and coordinate the multiple processes seen in the 
inflammation. The major mediators implicated in the pathogenesis of asthma are; 
 
1.Cytokines 
Cytokines are small molecular weight glycosylated proteins. Cytokines is a 
broad term and it includes several mediators like interleukins, interferons and 
growth factors. Asthma shows the involvement of variety of cytokines like IL-1, 
IL-2, IL-3, IL-4, IL-5, IL-13, IL-18, TNF-α(Tumour Necrosis Factor-α), 
FGF(Fibroblast Growth Factor), PDGF(Platelet Derived Growth Factor), 
VEGF(Vascular Endothelial Growth Factor). These are responsible for 
recruitment and proliferation of leukocytes, airway hyperresponsiveness, mucus 
hypersecretion, increased vascular permeability, fibroblast activation.(2,3) 
 
2.Chemokines 
This family of small molecular weight proteins are classified into 4 types 
based on the arrangement of cysteine residues- XC, CC, CXC, CX3C. Their major 
function in asthma is recruitment of other inflammatory cells by acting as 
chemoattractant.(2) 
 
3.Leukotrienes 
Leukotrienes are synthesized in eosinophils and mast cells from 
arachidonic acid. They are responsible for causing bronchoconstriction, increased 
mucus secretion and increased vascular permeability seen in asthmatics.(2) 
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4.Prostanoids 
These are also derived from arachidonic acid. PGD2, PGF2, TXA2 acts as 
bronchoconstrictors and also recruit other inflammatory cells of these PGD2 plays 
a predominant role in asthma. 
 
5.Nitric oxide 
Increased expression of inducible nitric oxide synthase due to chronic 
inflammation results in increased production of nitric oxide in the airways. Nitric 
oxide causes cellular injury by promoting free radical formation. 
 
Other mediators involved are 
1.Histamine 
2.Platelet Activating Factor 
3.Endothelin(2,13) 
 
VARIOUS CELLS AND MEDIATORS INVOLVED IN ASTHMA 
 
17 
 
The repeated cycles of inflammation characterised by infiltration of 
eosinophils, mast cells, lymphocytes and elaboration of inflammatory mediators 
like interleukins, chemokines and growth factor leads to chronic inflammation of 
airway which is detrimental and injurious to airway.(2,3) 
 
EFFECTS OF CHRONIC INFLAMMATION 
 Bronchial asthma shows continuous inflammation and repair 
simultaneously. This chronic inflammation causes characteristic changes which 
are collectively referred as airway remodelling. 
 
Various changes seen in airway remodelling are 
i. Airway epithelium 
 Chronic inflammation leads to epithelial damage which in turn leads to 
airway hyperresponsiveness due to loss of epithelial barrier function (leads to 
increased penetration of allergens), loss of enzymatic activity such as neutral 
endopeptidase which normally degrades various inflammatory mediators, 
exposure of sensory nerve endings leading to enhanced reflex neural effects on 
bronchomotor tone.(3) 
 
ii. Fibrosis 
 Basement membrane of airways is thickened due to sub epithelial fibrosis 
with deposition of type III and V collagen due to release of profibrotic mediators 
such as Transforming Growth Factor β (TGFβ). This fibrosis results in 
irreversible narrowing of airways.(3) 
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iii. Airway smooth muscle 
 Bronchial smooth muscle cells show hypertrophy and hyperplasia due to 
simulation by growth factors such as platelet derived growth factor (PDGF). 
Inflammatory mediators may also modulate ion channels that regulate resting 
membrane potential of bronchial smooth muscle cells which alters the excitability 
of smooth muscle cells.(3) 
 
iv. Blood vessels 
 There is increase of airway mucosal blood vessels due to stimulation of 
angiogenesis by vascular endothelial growth factor (VEGF). Chronic 
inflammation also results in microvascular leakage leading to airway edema and 
exudation.(3) 
 
v. Mucosal glands 
 Chronic inflammation leads to hyperplasia of submucous glands and 
increase in number of goblet cells leading to mucous hypersecretion and 
formation of viscid mucous plugs.(3) 
 
vi. Nerves 
 Inflammatory mediators may also activate sensory nerve fibres resulting in 
reflex cholinergic mediated bronchoconstriction and also increase the sensitivity 
of sensory nerve endings to external stimuli such as allergens. (3) 
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vii. Changes in pulmonary function 
 Limitation of airflow is due to bronchoconstriction, edema, congestion, 
exudation and airway remodelling leading to decrease in FEV1, FVC, PEFR. (3) 
 
AIRWAY REMODELLING 
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MORPHOLOGY OF LUNGS IN BRONCHIAL ASTHMA 
Various features seen are  
 Occlusion of bronchi and bronchioles by thick tenacious mucous plugs. 
 Curshmann spirals are seen in sputum. These are formed due to extrusion 
of mucous plugs from sub epithelial mucosal gland ducts. 
 
 Charcot Layden Crystals are also seen in sputum. These are composed of 
eosinophilic protein called galectin 10. 
 
 Creola bodies are also seen in sputum. These are formed from shed 
epithelial cells.(3) 
 
Microscopic features seen in chronic asthmatics are  
a. Thickening of airway wall 
b. Sub epithelial basement membrane fibrosis 
c. Increased vascularity 
d. Increase in submucosal glands 
e. Hypertrophy and hyperplasia of bronchial smooth muscle cells(3) 
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MORPHOLOGIC FEATURES OF BRONCHIAL ASTHMA 
 
 
 
CLINICAL FEATURES 
SYMPTOMS 
 Episodic wheezing 
 Chest tightness 
 Difficulty in breathing 
 Cough with excess of sputum production 
 
  Seasonal variability of symptoms is seen. Family history of atopy may be 
present. The frequency of symptoms is highly variable. Usually asthma is worse at 
night due to circadian variation in bronchomotor tone between 3 to 4 am leading 
to increased occurrence of bronchoconstriction. Hence patients typically awake 
with symptoms in early morning.(5,14,15) 
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PHYSICAL EXAMINATION 
 Asthmatic patients are usually normal between exacerbation. Bilateral 
wheezing may be present. In severe cases decreased breath sounds, usage of 
accessory muscles is seen. 
 
The severity and frequency of symptoms varies greatly between patients 
and also in the same patient.(5,14,15) 
 
DIAGNOSIS 
1.Lung Function Tests 
 Spirometry shows reduced forced expiratory volume in the first second 
(FEV1), Forced Vital Capacity (FVC), FEV1/FVC returns and Peak Expiratory 
Flow Rate (PEFR). 
 
 Reversibility of the lung volumes is diagnostic of bronchial asthma greater 
than 12% and 200ml increase in FEV1 15 minutes after administration of inhaled 
short acting beta agonists shows the reversibility. 
 
 Airway hyperresponsiveness can be demonstrated by methacholine or 
histamine challenge where a decrease in FEV1 by 20% is suggestive of airway 
hyperresponsiveness. However, this is rarely done. 
 
 Exercise testing can also be done.(1) 
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2.Chest X-Ray 
 Usually normal in patients with asthma. Chest X-ray is primarily used to 
exclude other causes of respiratory symptoms. In patients with severe disease 
hyperinflated lungs are seen. 
 
3.Electrocardiogram 
 Normal in asthmatics. In acute severe asthma ECG may show sinus 
tachycardia, P-pulmonale, right axis deviation, right bundle branch block, 
arrythmias. 
 
4. Haematologic tests 
 Eosinophilia may be seen in asthmatic patients. In patients taking 
corticosteroids eosinophil value may be normal. 
 
 Increased total serum IgE, increased IgE to inhaled allergens may be 
present in patients with atopic asthma. 
 
5. Skin tests for allergens may be positive in patients with atopic asthma. 
 
6. Exhaled nitric oxide  
 Non-invasive test to measure airway inflammation, as increased bronchial 
inflammation leads to increased exhaled nitric oxide. It is also used to test 
compliance (Inhaled corticosteroid decreases exhaled nitric oxide), to titrate dose 
of inhaled corticosteroids.(1,16) 
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MANAGEMENT OF BRONCHIAL ASTHMA 
Treatment should be individualized for every patient and the patients 
should be monitored regularly with modification in treatment dose as and when 
required. 
 
Aims of treatment are 
a) Abolish symptoms  
b) Reduce the risk of exacerbations 
c) Restore lung function 
d) Eliminate emergency visits 
e) Maintain normal levels of physical activity 
f) Minimize adverse effects(17) 
 
Management of bronchial asthma involves 
1.ASSESSING AND MONITORING ASTHMA SEVERITY AND ASTHMA 
CONTROL 
 Severity is the intrinsic intensity of the disease process. Control is the 
degree to which symptoms and limitations of physical activity are minimized by 
treatment. Control includes impairment and risk. Impairment is the frequency and 
intensity of symptoms and functional limitations. Risk is the likelihood of acute 
exacerbations or the chronic decline in lung functions.(5) 
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Classification of Asthma Severity(5) 
Components 
of Severity Intermittent Mild Moderate Severe 
Symptoms ≤ 2 days/week 
> 2 
days/week 
but not daily 
Daily Throughout the day 
Night time 
awakenings ≤ 2x/month 3-4x/month 
> 1 x/week 
but not 
nightly 
Often 
7x/week 
Short-acting 
β2-agonist use 
for symptom 
control 
≤ 2 days/week 
 
> 2 
days/week 
but not 
daily, and 
Daily not 
more than 1 
x on any day 
Daily 
Several times 
per day 
 
Interference 
with normal 
activity 
None Minor limitation 
Some 
limitation 
Extremely 
limited 
Lung function 
• Normal FEV1 
between 
exacerbations 
• FEV1 > 80% 
predicted 
• FEV1/FVC 
normal 
• FEV1 > 
80% 
• 
FEV1/FVC 
normal 
• FEV1 > 60% 
but predicted 
< 80% 
predicted 
• FEV1/FVC 
reduced 5% 
 
• FEV1 < 60% 
predicted 
• FEV1/FVC 
reduced > 5% 
Recommended 
Step for 
Initiating 
Treatment 
Step 1 Step 2 
Step 3 and 
consider short 
course of oral 
systemic 
corticosteroids 
Step 4 or 5 
and consider 
short course 
of oral 
systemic 
corticosteroids 
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Classification of Asthma Control(5)  
Components of 
Control Well Controlled 
Not Well 
Controlled 
Very Poorly 
Controlled 
Symptoms ≤ 2 days/week > 2 days/week Throughout the day 
Night time 
awakenings ≤ 2x/month 1 -3x/week ≥ 4x/week 
Interference with 
normal activity None Some limitation Extremely limited 
Short-acting beta-
2-agonist use for 
symptom control 
≤ 2 days/week > 2 days/week Several times/day 
FEV1 or peak 
flow > 80% predicted 60-80% predicted < 60% predicted/ 
Validated 
Questionnaires 
ATAQ 
0 1 -2 3-4 
ACQ ≤ 0.75 ≥ 1 .5 N/A 
ACT ≥ 20 1 6-1 9 ≤ 1 5 
Recommended 
Action for 
Treatment 
Maintain current 
step 
Regular follow-
ups every 1 -6 
months to 
maintain control. 
Consider step 
down if well 
controlled for at 
least 3 months. 
Step up 1 step 
Re-evaluate in 2-
6 weeks. 
 
Consider short 
course of oral 
corticosteroids, 
Step up 1 -2 
steps, and re-
evaluate in 2 
weeks. 
 
 
2.PATIENT EDUCATION 
 It involves explaining the patient about asthma, its management, proper 
inhaler use and adverse effects of treatment. 
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It has many positive effects like reducing the need for emergency visits, 
reducing incidence of hospitalization, improving compliance and improving 
control. Patient should be taught to recognize symptoms of inadequate control, to 
use reliever medications. Patient should be asked to maintain a dairy listing 
exacerbations, triggers, use of reliever medications, PEFR values. Written 
personal action plan to be followed in case of increasing symptoms can be given 
for patients. This should be clear, simple and individualized. However, this can 
lead to overtreatment and increased adverse effects.(2,5) 
 
3. CONTROL OF ENVIRONMENTAL FACTORS AND COMORBID 
ILLNESS THAT INFLUENCE BRONCHIAL ASTHMA 
 Significant reduction of exposure to allergens, irritants reduce the 
symptoms, improve control, reduce the need for medications. 
 
 Comorbid illness that may significantly influence the pathology of asthma 
like gastro oesophageal reflux disease, obesity, rhino sinusitis, obstructive sleep 
apnoea should be managed appropriately.(5) 
 
4. PHARMACOLOGIC AGENTS 
There are two major class of pharmacological agents viz, bronchodilators 
and anti-inflammatory agents. Bronchodilators are mainly used as reliver(rescue) 
medications. These agents act principally by relaxing of bronchial smooth muscle 
and thereby reversing the airflow obstruction. Anti-inflammatory agents 
especially corticosteroids are mainly used as chronic controllers. These agents 
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reduce airway inflammation and helps to maintain long term control over 
asthma.(5) 
 
Various approaches to treatment are 
1. Prevention of Antigen Antibody reaction—avoidance of antigen, 
desensitization. 
2. Neutralization of IgE  
3. Suppression of inflammation and bronchial hyperreactivity. 
4. Prevention of release of mediators. 
5. Antagonism of released mediators - leukotriene antagonists, 
antihistamines, PAF antagonists. 
6. Blockade of bronchoconstrictor neurotransmitter. 
7. Mimicking bronchodilator neurotransmitter. 
8. Directly acting bronchodilators.(18) 
 
CLASSIFICATION 
I. Bronchodilators 
A. β2 Sympathomimetics:  
 Salbutamol, Terbutaline, Bambuterol, Salmeterol, Formoterol. 
B.  Methylxanthines: 
 Theophylline (anhydrous), Aminophylline, Hydroxyethyl theophylline, 
 Doxophylline. 
C.  Anticholinergics: 
 Ipratropium bromide, Tiotropium bromide. 
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II. Leukotriene antagonists 
 Montelukast, Zafirlukast. 
 
III. Mast cell stabilizers 
 Sodium cromoglycate, Ketotifen. 
 
IV. Corticosteroids 
A. Systemic:  
 Hydrocortisone, Prednisolone, Betamethasone, Dexamethasone 
B. Inhalational:  
 Beclomethasone dipropionate, Budesonide, Fluticasone propionate, 
 Flunisolide, Ciclesonide. 
 
V. Anti-IgE antibody 
 Omalizumab(18) 
 
BRONCHODILATORS 
 Relax the bronchial smooth muscle and cause immediate reversal of airway 
obstruction. 
 
Bronchodilators include 3 main class of drugs viz, 
a) β2 agonists 
b) Methylxanthines 
c) Anticholinergic agents(4) 
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β2 AGONISTS 
β2 agonists are the bronchodilator of choice in acute exacerbations and in 
chronic persistent asthma because they are most effective than other 
bronchodilators and have minimal adverse effects. Though other 
sympathomimetics are also effective in bronchial asthma selective β2 agonists are 
the preferred agents now because of minimal cardiac adverse effects. Because of 
minimal systemic adverse effects, rapid duration of action; inhalation is the 
preferred route of administration for β2 agonists; oral therapy is reserved for 
patients who cannot use inhalers properly and in cases of severe asthma.(4)  
 
Mechanism of Action:  
β2 agonists cause activation of β2 receptors (Gs subtype)-adenyl cyclase- 
cyclic AMP- Protein kinase A pathway resulting in bronchial smooth muscle 
relaxation. 
 
Other effects include 
 Inhibition of inflammatory mediator release. 
 Reduction in microvascular leakage. 
 Reduction in cholinergic mediated bronchoconstriction by acting on 
presynaptic Β2 receptors leading to inhibition of acetylcholine  
release.(4,19-21) 
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MECHANISM OF ACTION OF β2 AGONISTS  
 
 
 
CLASSIFICATION OF β2 AGONISTS 
1.Short Acting Beta Agonist (SABA) 
 Acts for 3-4 hours 
 Includes Salbutamol, Terbutaline, Pirbutaline 
 
2.Long Acting Beta Agonist (LABA) 
 Acts more than 12 hours 
 Includes Salmeterol, Formoterol 
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3.Very Long Acting Beta Agonist 
 Acts more than 24 hours 
 Includes Indacaterol, Vilanterol, Oladaterol(4,18) 
 
 LABA improves asthma control and reduces the risk of exacerbations. In 
asthmatic patients LABAs should never be used alone as they don’t treat the 
underlying pathology i.e., chronic inflammation and this can lead to increased risk 
of near fatal asthma exacerbations. So LABAs should always be used in 
combination with inhaled corticosteroid as a fixed dose combination. 
 
LABAs are an effective add-on therapy with the ICS and helps to achieve 
control without increasing the dose of ICS. Also, the combination of LABA with 
ICS is synergistic and helps to improve patient compliance.(4,22,23) 
 
Adverse effects:  
 These are mainly due to stimulation of β2 receptors in extrapulmonary sites 
and includes  
 Muscle tremor, most common adverse effect; due to the stimulation of 
skeletal muscle of β2 receptors. 
 Tachycardia, palpitation due to stimulation of cardiac β2 receptors. 
 Hypokalaemia, due to enhanced potassium entry into skeletal muscle 
mediated by β2 receptors. 
 Increase in serum glucose, lactose, free fatty acid levels.(4,18) 
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TOLERENCE TO β2 AGONISTS 
Seen with chronic treatment with beta 2 agonists because of down 
regulation of β2 receptors. However due to unknown reasons, tolerance doesn’t 
develop bronchodilator action of β2 agonists, but tolerance develops to other 
actions of β2 agonists.(4) 
 
ANTICHOLONERGIC AGENTS 
Mechanism of Action:  
Inhibit the bronchoconstrictor effect of acetylcholine by acting as 
antagonist at M3 receptor in bronchial smooth muscle cell leading to 
bronchodilation. They also decrease the mucous secretion.(4,19) 
 
Classification: 
1.Short Acting Muscarinic Antagonists (SAMA) 
 Act for 6-8 hours 
 Include Ipratropium 
2.Long Acting Muscarinic Antagonists (LAMA) 
 Act for more than 24 hours 
 Include Tiotropium, Umeclidinium, Aclidinium 
 
Uses: 
 They are less effective bronchodilators. Anticholinergics are used mainly 
as an add-on bronchodilator in patients not controlled adequately on inhaled β2 
agonists. The combination of anticholinergic agents with β2 agonists is additive 
and more beneficial than individual agents in patients with severe asthma.(4,18,22,23) 
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Adverse effects:  
Includes bitter taste, dryness of mouth, urinary retention, anticholinergics 
may precipitate glaucoma in elderly.(4,18) 
 
METHYLXANTHINES 
Methylxanthines are one of the earliest drugs used in asthma, in usage 
since 1930s. These are chemically related to caffeine. 
 
Mechanism of Action:  
Proposed mechanisms of action are 
a. Nonselective inhibition of phosphodiesterase enzyme leading to increased 
intracellular levels of cyclic AMP which in turn leads to bronchodilatation. 
b. Adenosine receptor antagonism. Adenosine acts as bronchoconstrictor in 
bronchial asthma by promoting the release of inflammatory mediators like 
leukotrienes and histamine. 
c. Increasing the release of anti-inflammatory interleukin 10. 
d. Reducing the expression of inflammatory genes by preventing the 
translocation of proinflammatory transcription factor Nuclear Factor kappa 
B(NFκB). 
e. Promoting apoptosis of eosinophils and neutrophils by reducing the 
intracellular levels of anti-apoptotic protein BCl-2.(4,19,20,22)    
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ACTIONS OF METHYLXANTHINES 
 
 
 
Uses: 
 Methylxanthines have narrow therapeutic index. Optimal therapeutic levels 
include 5-15 mg/L. The dose required to achieve this level varies among 
individuals because of difference in drug clearance and hence individualization of 
dosage and therapeutic drug monitoring are recommended. 
 
They are less effective bronchodilators, so they are used mainly in patients 
who fail to respond or become intolerant to β2 agonists. 
 
 Oral methylxanthines- used as add-on agents. Sustained release 
formulations are preferred because immediate release preparation cause wide 
fluctuations in serum levels of methylxanthines and therefore have high frequency 
of adverse effects.  
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 Intravenous- Aminophylline, a water-soluble ester of theophylline is used 
in acute exacerbations.(4,18,22,23) 
 
Adverse effects:  
Include nausea, vomiting, headache, restlessness, abdominal discomfort, 
gastritis, diuresis. In toxic levels arrhythmias and seizure occur. Because of their 
low safety profile their use is currently declining.(4,18) 
 
CORTICOSTEROIDS 
Mechanism of Action 
Corticosteroids bind to glucocorticoid receptor (GR) and this complex 
translocate to the nucleus, binds to specific sequences of DNA called 
Glucocorticoid Responsive Elements and modify transcription, leading to various 
effects. 
 
MECHANISM OF ACTION OF CORTICOSTEROIDS 
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Corticosteroids have profound anti-inflammatory action. This is due to its action 
on various processes involved in inflammation such as 
a) Reduction in cytokine production 
b) Inhibition of MAP kinase signalling pathway 
c) Reducing eosinophil survival 
d) Reduction in airway hyperresponsiveness 
e) Reducing the number of T lymphocytes, mast cells in lungs 
f) Improving vascular permeability thereby reducing exudation(4,18-19,22-23) 
 
ACTIONS OF CORTICOSTEROIDS 
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CORTICOSTEROIDS AND β2 AGONISTS 
Corticosteroids potentiate β2 agonists by 
a) Preventing or reversing β receptor desensitization 
b) Preventing or reversing β receptor uncoupling 
c) Promoting the transcription of β receptor gene thereby increasing the 
availability of β receptors(4) 
 
Available Inhaled Corticosteroids and Long Acting Beta 2 Agonists combinations 
are; 
1. Beclomethasone - Formoterol 
2. Budesonide - Formoterol 
3. Fluticasone - Formoterol 
4. Mometasone - Formoterol 
5. Fluticasone – Salmeterol 
6. Fluticasone – Vilanterol 
 
Various routes used are 
INHALED CORTICOSTEROIDS (ICS) 
These are the first line agents in patients with chronic persistent asthma. 
Inhaled corticosteroids are used in any patient requiring the use of SABA more 
than 2 times per week. Usually Inhaled corticosteroids are started at minimal dose 
and titrated as per clinical response. Systemic absorption of ICS can occur from 
the particles deposited at oropharynx, airway and alveolus surface. This systemic 
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absorption can be minimized with the help of spacers and also by rinsing mouth 
after ICS usage.(4,18) 
 
Comparative doses of inhaled corticosteroids(4,5) 
Medication Low Daily Dose 
Medium 
Daily Dose 
High Daily 
Dose 
Beclomethasone 
40 or 80 mcg/puff 80-240 mcg 240-480 mcg > 480 mcg 
Budesonide 
90, 180, or 200 mcg/puff 180-600 mcg 600- 1200 mcg > 1200 mcg 
Flunisolide 
250 mcg/puff 500- 1000 mcg 
1000-2000 
mcg > 2000 mcg 
Flunisolide 
80 mcg/puff 320 mcg 320-640 mcg > 640 mcg 
Fluticasone 
44, 110, or 220 mcg/puff 88-264 mcg 264-440 mcg > 440 mcg 
Mometasone 
200 mcg/puff 200 mcg 400 mcg > 400 mcg 
Triamcinolone acetonide 
75 mcg/puff 300-750 mcg 750-1500 
mcg > 1500 
mcg 
 
ORAL CORTICOSTEROIDS 
Prednisolone is the most commonly used oral corticosteroid and it is 
usually used as a short course during acute severe asthma and the dose is 
gradually tapered over 1 week after the exacerbation has resolved. 
 
Prednisolone is given as a single dose in morning to minimize the risk of 
adrenal suppression as the morning dose coincides with the normal diurnal 
increase in plasma cortisol levels.(4,18) 
 
PARENTAL CORTICOSTEROIDS (INTRAVENOUS) 
Hydrocortisone is the preferred agent because of its rapid onset of action; 
intravenous corticosteroids are used in patients with acute severe asthma.(4,18) 
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Adverse Effects: 
Local Adverse Effects of ICS 
 Hoarseness of voice, dysphonia 
 Oropharyngeal candidiasis 
 Throat irritation, cough 
 
These can be minimized using spacers or by rinsing mouth after ICS usage. 
Systemic Adverse Effects 
 Osteoporosis 
 Hypertension 
 Impaired glucose tolerance, Diabetes mellitus 
 Cataract, Glaucoma 
 Peptic ulcer 
 Weight gain, fluid retention 
 Hypothalamo-pituitary-adrenal axis suppression 
 Psychosis 
 Dermal thinning, capillary fragility 
 Growth suppression in children(4,18,19) 
 
ANTILEUKOTRIENES 
Leukotrienes play an important role in the pathogenesis of bronchial 
asthma by causing increased vascular permeability, bronchoconstriction, 
exudation and mucous hypersecretion. 
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Hence inhibition of synthesis of leukotrienes by inhibitory 5-lipo 
oxygenase and antagonising the actions of leukotrienes at the level of cysteinyl 
leukotriene(cys-LT) receptor improves the control of bronchial asthma. 
 
Antileukotrienes agents have anti-inflammatory property, but they are less 
effective anti-inflammatory agents than ICS. Hence, they are used mainly as an 
add-on agent.(4,18,19,24) 
 
Classification: 
1. Cys-LT receptor antagonist- Monteleukast, Zafirleukast. 
2. 5-lipo oxygenase inhibitor- Zileuton.(18) 
 
ACTIONS OF ANTILEUKOTRIENES 
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Adverse effects: 
 Hepatic dysfunction, nausea, headache, gastrointestinal distress.(4)  
 
MAST CELL STABILIZERS 
 Includes the cromones - cromolyn sodium, nedocromil. 
 
Mechanism of Action: 
Cromones stabilize the mast cell membrane by preventing the influx of 
calcium ions provoked by antigen IgE reaction and hence prevent degranulation 
and the cascade of events leading to exacerbations. They also reduce leukocyte 
chemotaxis and activation.  
 
Cromones are available as a metered dose inhaler, given 3-4 times 
daily.(4,18) 
 
Adverse Effects: 
 Throat irritation, dryness of mouth, headache. 
 
 However, their use has declined with the advent of more effective inhaled 
corticosteroids.(4,18) 
 
ANTI IgE THERAPY 
 Omalizumab – Humanized monoclonal antibody to IgE. 
 
Mechanism of Action:  
Omalizumab blocks binding of IgE to its receptor on mast cells and thereby 
preventing their activation by allergens. 
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Omalizumab also decrease the levels of IgE in circulation and also reduce 
the need for oral and inhaled corticosteroids and the number of 
exacerbations.(4,18,19,24)   
 
MECHANISM OF ACTION OF OMALIZUMAB 
 
Omalizumab is used mainly in severe cases of bronchial asthma. It is given 
as subcutaneous injection every 2-4 weeks. However, it is very costly. 
 
Adverse Effects:  
 Injection site reactions (pain, redness, swelling) 
 Anaphylaxis(4,18) 
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IMMUNOSUPPRESANTS: 
Methotrexate, cyclophosphamide, intravenous immunoglobins are used 
when bronchial asthma is not adequately controlled with other agents or to as 
steroid sparing therapy. 
 
Their disadvantages are  
- Costly 
- Less effective 
- More adverse events(4,18) 
 
NEWER DRUGS IN DEVELOPMENT 
NOVEL BRONCHODILATORS: 
 
1.MAGNESIUM SULPHATE 
Magnesium sulphate is used as nebulized form or intravenous injection in 
patients with acute severe asthma. It acts by decreasing cytosolic calcium levels in 
bronchial smooth muscle cells and thereby causing bronchodilatation. Adverse 
effects include flushing, nausea. 
 
2.POTASSIUM CHANNEL OPENER – CROMAKALIM 
Acts by opening K+ ATPase in bronchial smooth muscle leading to 
hyperpolarization and thereby relaxation. Cardiovascular side effects especially 
postural hypotension limits the oral dose. Inhaled formulations are much effective. 
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3.VASOACTIVE INTESTINAL PEPTIDE ANALOGS 
VIP is a bronchodilator; however, it cannot be used therapeutically because 
of its very short half-life of 2 minutes. Newer drugs acting as VIP analogs are 
under clinical trial. 
 
Other newer class of drugs in development are 
i. Rho kinase inhibitor 
ii. Myosin light chain kinase inhibitors 
iii. PAF (Platelet Activating Factor) antagonists 
iv. Anti-IL-5 antibody (Mepolizumab)   
v. Anti-IL-13 antibody 
vi. Chemokine receptor antagonists 
vii. MAP kinase inhibitor-Losmapimod 
viii. NFκB inhibitor(4,18,19,22–24) 
 
STEPWISE TREATMENT 
Stepwise approach to asthma treatment is the description of levels of treatment 
required to achieve control. Various medications are adjusted up or down in a 
stepwise manner to achieve symptom control, minimise exacerbations and 
minimise adverse effects of medications. If patient has persistent symptoms or 
exacerbations in spite of treatment, consider the following before stepping up the 
treatment 
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 Poor compliance 
 Persistent exposure to allergens, drugs, precipitants 
 Incorrect inhaler technique 
 Presence of comorbid illness that influence asthma management 
 
Step 1:   Occasional symptoms, less frequent than daily 
Step 2:  Daily symptoms 
Step 3:  Severe symptoms 
Step 4:  Severe symptoms uncontrolled with high dose inhaled corticosteroids 
Step 5:  Severe symptoms and deteriorating (5,22,23) 
 
STEP WISE TREATMENT OF BRONCHIAL ASTHMA 
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STEP DOWN 
 Stepping down of treatment is done in patients with stable symptoms and 
stable peak flow meter readings. This is done by assessing the patient’s control 
every 3 months. Stepping down therapy helps to reduce adverse events and cost of 
therapy.(1,5,22) 
 
REFRACTORY ASTHMA 
 Refractory asthma is seen in 5% of patients. These patients remain 
symptomatic despite the use of maximal dose of inhaled corticosteroids. It is of 
two types; 
 Corticosteroid dependent asthma – These patients require high dose of oral 
corticosteroids to achieve asthma control. 
 Corticosteroid resistant asthma – These are the patients who fail to respond 
to high dose oral corticosteroids. 
 
 Management of these patients is difficult, and it involves checking 
compliance, inhaler technique, smoking cessation, appropriate treatment of 
comorbid disease that aggravate asthma, control of exposure to allergens or 
environmental triggers. Drugs like omalizumab, immunosuppressants can be used 
in these patients. However, the success of these therapies is not satisfactory.(1,2,22) 
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VITAMIN D 
INTRODUCTION 
 Vitamin D or Cholecalciferol is a fat-soluble vitamin synthesized in the 
body from steroids by the action of ultraviolet rays on skin and also present in 
food. Vitamin D is a prohormone with several active metabolites that acts as 
hormones.(6) 
 
HISTORY 
 The first scientific description of Rickets was written in the 17th century by 
Dr. Daniel Whistler and Prof. Francis Glisson. 
 
 Sir Edward Mellanby was the first are to conclude that rickets may be a 
dietary deficiency. 
 
Prof. Elmer McCollum developed experimental rickets in dogs and cured 
rickets by treating them with cod liver oil in which vitamin A is removed by 
oxygenation. And he concluded that this is a new vitamin which he named as 
vitamin D. 
 
Huldshinsky and Chick et al discovered that children with rickets could be 
cured by exposure to sunlight or UV light thereby hypothesizing that sunlight or 
UV light plays a role in vitamin D metabolism. 
 
Vitamin D2 was the first to be isolated in 1932 by Askew et al; later 
Windaus and Bock identified vitamin D3 in 1937. 
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Nicolaysen discovered the role of vitamin D in intestinal calcium 
absorption. Carlsson and Bauer discovered the role of vitamin D in bones. 
 
Fraser and Kodicek discovered 1, 25 OH D3 and also conversion of 25 OH 
D3 to 1, 25 OH D3 in kidney.(25) 
 
STRUCTURE 
 Vitamin D is a secosteroid. Secosteroids are those in which one of the rings 
are broken. The ring structure of vitamin D is derived from cyclo pentano 
perhydro phenanthrene ring of steroids.(6) 
 
STRUCTURE OF VITAMIN D2, D3 AND CALCITRIOL 
 
SOURCES 
 Vitamin D occurs in two forms - ergocalciferol (D2) and 
cholecalciferol(D3)  
 
 Ergocalciferol is chiefly found in plant sources and fungi. 
 
50 
 
 Cholecalciferol is chiefly found in animal sources like fish liver oil, fish, 
egg yolk. Cholecalciferol is also synthesized in skin from sunlight. 
 
 Cholecalciferol has 10 times greater potency than ergocalciferol due to 
long half-life (t1/2) of cholecalciferol and greater affinity of cholecalciferol for 
vitamin D receptor.(6,26) 
 
BIOSYNTHESIS OF VITAMIN D 
 Vitamin D3 is synthesized in the skin from 7–dehydrocholesterol by the 
action of ultraviolet rays specifically UVB – 290 to 310 nm. 
 
 The source of 7–dehydrocholesterol are the sebaceous glands which secrete 
7–dehydrocholesterol uniformly onto the surface. The concentration of 7–
dehydrocholesterol varies according to depth from surface with highest 
concentration in Malphigian layer of skin. 
 
Determinants of vitamin D3 synthesis in skin are 
 Season 
 Latitude 
 Time spent outdoors 
 Skin pigmentation 
 Usage of sunscreens 
 Skin thickness(6,26) 
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 Vitamin D3 as such does not have significant biological activity. It must be 
converted to its metabolically active form by hydroxylation to 1,25 dihydroxy 
cholecalciferol.(26–28)  
 
This occurs in two steps 
1. 25-Hydroxylation 
Occurs in liver by vitamin D 25 hydroxylase, a cytochrome P450 dependent 
mixed function oxidase. This 25OHD3 is secreted to the plasma. 25OHD3 is the 
major circulating form with t1/2 of 19 days.(6,29) 
2. 1-hydroxylation 
Occurs in kidney specifically in proximal tubular epithelial cells 
(mitochondria) with the help of 1 α hydroxylase. This step is highly regulated 
by negative feedback mechanism. t1/2 of 1,25OHD3 is 3-5 days.(6,29) 
 
BIOSYNTHESIS OF VITAMIN D 
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REGULATION OF VITAMIN D SYNTHESIS 
 Vitamin D synthesis is regulated at the level of 1 α hydroxylase in renal 
cells. Activity of 1 α hydroxylase is increased when the serum calcium is low, 
serum phosphate is low, vitamin D levels are low. 
 
High circulating levels of 1,25OHD3 decreases the activity 1 α 
hydroxylase. The major hormone involved in regulating 1 α hydroxylase activity 
is parathyroid hormone(PTH) which simulates vitamin D synthesis when serum 
calcium levels are low and suppresses vitamin D synthesis when serum calcium 
levels are high.(6,27,30) 
 
REGULATION OF VITAMIN D SYNTHESIS 
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MECHANISM OF ACTION OF CHOLECALCIFEROL 
 1, 25 OH D3 is the functionally active form of vitamin D and this active 
form acts by binding to a specific intracellular receptor-the vitamin D 
receptor.(6,30) 
 
VITAMIN D RECEPTOR(VDR) 
 Vitamin D receptor belongs to the steroid family of receptors and it is 
present in bone, kidney, intestine, as well as in various immune, endocrine, skin 
cells. This shows that the role of vitamin D is not only limited to calcium 
homeostasis. 
 
 Binding of 1, 25 OHD3 to VDR leads to its heterodimerization with 
another intracellular receptor called retinoid X receptor(RXR). This complex 
translocates to nucleus. 
 
Inside the nucleus, vitamin D receptor complex binds to vitamin D 
response elements(VDRE) leading to changes in transcription of mRNA. Mostly 
vitamin D activates transcription however in some cases vitamin D suppresses 
transcription such as in IL-2(Interleukin-2), IFN(Interferon) gamma. 
 
 Various genes regulated by vitamin D are genes involved in mineral 
homeostasis, cellular metabolism, cell proliferation, cell differentiation, hormonal 
signalling, oncogenes, vitamin D metabolism. 
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 There is also evidence for some non-genome mediated actions of vitamin 
D like rapid transport of calcium across intestine, PKC (Protein Kinase C) 
activation, MAPK (Mitogen Activated Protein Kinase) activation and calcium 
signalling.(6,27,28,30) 
 
MECHANISM OF ACTION OF VITAMIN D 
 
 
 
PHYSIOLOGICAL EFFECTS OF VITAMIN D 
INTESTINE 
 Vitamin D increases the absorption of calcium and phosphate in small 
intestine by increasing 
 Uptake of calcium from intestinal lumen to enterocytes by increasing the 
expression of calcium binding proteins such as calbindin and calmodulin. 
 Translocation of calcium across cell to the basolateral membrane 
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 Active transport of calcium into circulation by Ca2+ ATPase 
 Na+/ phosphate cotransporter(6,26,27) 
 
KIDNEY 
 Vitamin D increases reabsorption of calcium and phosphate by increasing 
the activity of calbindin, Na+/ phosphate cotransporter(6,26) 
 
BONES 
 It is the predominant target organ of vitamin D. Vitamin D regulates both 
bone formation(mineralization) and calcium metabolism(demineralization). 
Vitamin D acts predominantly on osteoblasts and osteoprogenitor cells. Absence 
of vitamin D leads to failure of mineralization and excess of demineralization 
thereby leading to soft and pliable bones.(6,26,27) 
 
EFFECTS OF VITAMIN D 
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OTHER EFFECTS 
 PANCREAS-Vitamin D has a positive effect on insulin secretion and is 
essential for normal pancreatic function 
 
 SKIN-Vitamin D regulates keratinocyte proliferation and differentiation 
 
 IMMUNE SYSTEM-Vitamin D regulates cytokine production, promotes 
differentiation of T regulatory cells and promotes phagocytosis. Deficiency of 
vitamin D is associated with increased inflammation. 
 
 SKELETAL MUSCLE-Vitamin D is essential for control of intracellular 
calcium levels thus affecting the excitability and contractibility of skeletal 
muscles. 
 
 BRAIN-Vitamin D acts like a neurosteroid and plays a role in brain 
development.(6) 
 
RECOMMENDED DAILY ALLOWANCE OF VITAMIN D(29) 
AGE GROUP VITAMIN D (IU/DAY) 
Infants 0 to 12 months 400 
Children aged >1 year- adults including 
pregnant and lactating women 600 
 
 No adverse events are seen with vitamin D3 supplementation up to 10000 
IU/day.(31) Most informative indicator of vitamin D status in body is serum 
25OHD3 levels.  
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Reference range for serum Vitamin D levels are(6) 
25-OH-D3 level ng/ml Status 
<20 Deficient 
21-29 Insufficient 
≥30 Adequate 
>150 Excess 
 
PHARMACOKINETICS 
ABSORPTION 
 Vitamin D is absorbed by non-saturable passive diffusion that is dependent 
on the presence of bile salts. Absorbed predominantly (90%) into the lymphatic 
circulation from where it enters the blood. 
 
TRANSPORT 
 Vitamin D3 is transported in plasma by binding to vitamin D binding 
protein or transcalciferin. Vitamin D binding protein is an α-globulin produced by 
liver and binds 90% of circulating metabolites of vitamin D. 
 
DISTRIBUTION 
 Vitamin D is distributed evenly among various tissues. Highest 
concentration is present in adipocytes. 
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METABOLISM 
 1, 25 OH D3 is converted to inactive metabolites such as 1, 24, 25 OH D3; 
1, 26, 25 OH D3; 1, 25 (OH)2 D3 23-26 lactone which are then conjugated with 
gluconic acid or sulfate. 
 
EXCRETION 
 Inactive metabolites are excreted primarily through bile.(6,31) 
 
FORMULATIONS OF VITAMIN D 
Various available formulations of vitamin D are 
1. Calciferol (Ergocalciferol, Vitamin D2) 
2. Cholecalciferol (Vitamin D3) 
3. Calcitriol (1,25 dihydroxy cholecalciferol)  
4. Alfacalcidol  
 
 It is 1 α-OH cholecalciferol—a prodrug. Alfacalcidiol is rapidly 
hydroxylated in the liver to 1,25 (OH)2 D3. Therefore, it does not require 1α 
hydroxylation which takes place in the renal cells. Alfacalcidiol is used in renal 
bone disease, vitamin D resistant rickets, hypoparathyroidism.  
 
5. Dihydrotachysterol 
 It is a synthetic analogue of ergocalciferol. However, it is less active than 
cholecalciferol formulations.(31) 
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DISEASE STATES 
VITAMIN D DEFICIENCY 
 Deficiency of cholecalciferol leads to rickets in children and osteomalacia 
in adults.(6,26) 
 
CAUSES OF DEFICIENCY 
PRIMARY 
 Due to inadequate supply of vitamin D because of dietary deficiency or 
inadequate exposure to sunlight, prolonged exclusive breast feeding (breast milk 
is a poor source of vitamin D). 
 
SECONDARY 
Due to impairment in absorption, metabolism of vitamin D 
 Gastro intestinal tract- malabsorption due to small bowel pathology, 
pancreatitis 
 Liver- impaired 25 hydroxylation in patients with chronic liver disease, 
hepatitis 
 Kidney- impaired 1 α hydroxylation in patients with renal failure 
 Drugs such as phenobarbitone, phenytoin which induce vitamin D 
catabolism hypoparathyroidism(6) 
 
Most prominent features of vitamin D deficiency are skeletal and neuromuscular. 
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RICKETS 
 Seen in children till the closure of epiphyseal growth plate. Deficiency of 
vitamin D causes impaired mineralization of bones leading to soft and pliable 
bones. Clinical features include bone pains, deformities of weight bearing bones 
like bow legs, knock knees, rickety rosary, pigeon chest, sabre tibia, delayed tooth 
eruption, muscle tenderness.(6,26) 
 
OSTEOMALACIA 
 Seen in older children and adults. Deficiency of vitamin D leads to 
insufficient mineralization of bones which makes them more prone to fractures 
especially fractures of wrist, pelvis. Other features are muscle weakness, bone 
pain and tenderness.(6,26) 
 
VITAMIN D TOXICITY 
Also called hypervitaminosis 
CAUSES: Usually due to overdosing on vitamin D supplements. 
 
 Hypervitaminosis leads to hypercalcemia and decrease in serum PTH 
levels. 
 
 Clinical features include anorexia, vomiting, headache, drowsiness, 
diarrhoea, polyuria, calcinosis, deposition of calcium and phosphate in soft tissues 
such as heart, kidney, blood vessels.(6,26) 
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DRUG INTERACTIONS 
 Bile salts binding resins such as cholestyramine and liquid paraffin 
decreases the intestinal absorption of vitamin D3. 
 
Antiepileptics- phenytoin and phenobarbitone increase the conversion of 
vitamin D3 to inactive metabolites and also reduce the responsiveness of target 
tissues to vitamin D3.(31) 
 
ROLE OF VITAMIN D IN DISEASE STATES 
1. IMMUNE SYSTEM 
 Vitamin D3 plays a protective role in many auto immune disease such as 
psoriasis, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, 
graft rejection, diabetes mellitus. 
 
2. Low serum vitamin D levels is a risk factor for cardiovascular disease 
3. Cholecalciferol is also proposed to have anticancer effect especially in colonic, 
breast, prostate cancer.(6) 
 
ROLE OF VITAMIN D IN BRONCHIAL ASTHMA 
Vitamin D influences the course and treatment of bronchial asthma in 
multiple ways.(32) Vitamin D deficiency is more common in asthmatic patients 
compared to general population as asthmatic patients tend to spend more time in 
doors, are less active physically and therefore their exposure to sunlight is 
less.(33,34)  
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Multiple studies have shown that low levels of vitamin D are associated 
with frequent exacerbations, more symptomatic disease, increased airway 
hyperresponsiveness, increased serum total IgE levels, eosinophilia, requirement 
of higher doses of corticosteroids, reduced pulmonary function- reduced FEV1, 
FVC; suboptimal response to corticosteroids, increased exhaled nitric oxide levels 
and frequent emergency visits. This shows that vitamin D deficiency is associated 
with severe disease.(7,8,35–51) 
 
Animal studies have shown that vitamin D reduces various features of 
airway inflammation like cellular infiltration, airway smooth muscle cell mass, 
goblet cell hyperplasia thereby reducing the features of airway remodelling seen 
in chronic asthma. Studies have also shown that vitamin D improves 
corticosteroid responsiveness in animal models of asthma.(38,46,52–54) 
 
In vitro studies have shown that vitamin D inhibits the proliferation of 
human airway smooth muscle cell by inhibiting the translocation and binding of 
NFκB, a stimulatory transcription factor and increasing the stability of IκBα, an 
inhibitor of NFκB activity; vitamin D also reduces the production of interleukins 
like IL 17,9,5 and IgE.(33,38) 
 
Several genes associated with bronchial asthma appear to be regulated by 
vitamin D.(33)  
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Various mechanisms by which vitamin D improves bronchial asthma are 
1. Reducing inflammation 
Vitamin D reduces airway inflammation by decreasing the production of 
proinflammatory cytokines like TNF alpha,(10,55) IL 17,5,22(9); increasing the 
production of anti-inflammatory cytokines like interleukin 10(7); inhibiting the 
activity of NFκB and increasing the activity of IκBα(9); increasing T regulatory 
cell activity; inhibiting the differentiation and maturation of mast cells(35); 
inhibiting the proliferation and differentiation of lymphocytes(56). This leads to 
reduced proliferation of bronchial smooth muscle cells due to down regulation of 
genes like VEGF, IL 6, fibronectin 1, slowing down of cell cycle thereby leading 
to more organised structure(7,10), reduced sub epithelial collagen deposition and 
reduced goblet cell hyperplasia(33). All these effects result in inhibition of airway 
remodelling, the key pathologic change seen in chronic asthma(35). Vitamin D also 
modulates dendritic cell function by reducing the expression of major 
histocompatibility complex, costimulatory molecules leading to reduction in 
downstream lymphocyte responses(33). 
 
2.Improving response to corticosteroids 
Vitamin D has a synergistic activity with corticosteroids. Vitamin D also 
enhances the various effects of corticosteroids like corticosteroid mediated 
induction of mitogen-activated protein 1, an anti-inflammatory protein. Vitamin D 
also reduces the expression of FKN, a steroid resistance gene and upregulates the 
expression of glucocorticoid receptor in various target cells like lymphocytes, 
eosinophils, bronchial smooth muscle cells(7,10,57). 
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3.Enhancing pulmonary immunity 
Vitamin D by improving pulmonary immunity reduces the risk of 
respiratory infection more specifically viral infections which are one of the most 
common precipitants of bronchial asthma. Vitamin D improves pulmonary 
immunity by increasing the levels of cathelicidin, defensin beta 2 which have 
antibacterial and antiviral activity. Vitamin D also modulates cytokine production 
in the event of respiratory infections resulting in enhanced pathogen clearance 
with limited inflammation(10,33). 
 
4.Lung development 
Vitamin D plays a role in the normal development of respiratory system. 
Vitamin D deficiency is associated with altered lung structure and impaired of 
pulmonary function leading to enhanced susceptibility to bronchial asthma(9). 
 
EFFECTS OF VITAMIN D IN BRONCHIAL ASTHMA 
 
Aim & Objectives 
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AIM & OBJECTIVES 
AIM: 
 To evaluate the efficacy and tolerability of Cholecalciferol as an add on 
therapy to standard treatment in modifying disease severity in adult patients with 
bronchial asthma. 
 
OBJECTIVES: 
PRIMARY OBJECTIVES: 
 To observe the change in severity of bronchial asthma by FEV1 (forced 
expiratory volume), FVC (Forced Vital Capacity) and PEFR (peak expiratory 
flow rate). 
 
SECONDARY OBJECTIVES: 
 To assess the number of exacerbations 
 To assess asthma control by asthma control questionnaire  
 To observe for any adverse effect with study drug 
 
  
Methodology 
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METHODOLOGY 
 
METHODOLOGY 
This prospective study was done to assess the therapeutic effect of 
Cholecalciferol in improving pulmonary function in bronchial asthma. 
 
 STUDY DESIGN:  
This study was a randomized, open label, prospective, parallel group, 
comparative study. 
 
STUDY CENTRE:  
Institute of Pharmacology in collaboration with Institute of Thoracic 
Medicine, Rajiv Gandhi Government General Hospital, Chennai. 
 
STUDY PERIOD:  
The study was carried out from June 2017 to March 2018. 
 
STUDY DURATION:  
Treatment period of 12 weeks and Post treatment follow up period of 4 
weeks per patient. 
 
SAMPLE SIZE:  
 N (No of participants in each group) = 2σ2[Z(α/2) + Z(β)]2/Δ2 (58) 
 Taking α=0.05, β=80% we get Z(α/2) =1.96, Zβ =0.842 
 σ (Standard deviation) =6.58, Δ (Difference between study groups) =5% 
 We get N= 27.15, adding 10% loss to follow up we get N=30.   
 Sample size=60 (Control group - 30, Study group - 30). 
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STUDY POPULATION:  
Adult patients with bronchial asthma with mild to moderate severity 
attending Thoracic Medicine OPD, RGGGH, Chennai. 
 
INCLUSION CRITERIA: 
1) Both genders. 
2) Age- 25 - 70 yrs. 
3) Patients with bronchial asthma on inhaled corticosteroids with FEV1 
>60%. 
4) Patients willing to give written informed consent. 
 
EXCLUSION CRITERIA: 
1) Pregnant and lactating women. 
2) Patients with evidence of clinically significant gastrointestinal, renal, 
respiratory, haematological, endocrinological, neurological, psychiatric or 
cardiovascular dysfunctions. 
3) Current smokers 
4) Patients already on vitamin D, calcium supplementations 
5) H/o intolerance to cholecalciferol. 
6) Patients taking drugs like beta blockers, non-steroidal anti-inflammatory 
drugs etc which are known to exacerbate bronchial asthma. 
7) Patient enrolled in any other study. 
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STUDY PROCEDURE: 
The study was conducted after obtaining the approval from the Institutional 
Ethics Committee, Madras Medical College and it is done in accordance with the 
Declaration of Helsinki & Good Clinical Practice (GCP) guidelines. 
 
Patients diagnosed with mild to moderate bronchial asthma attending the 
Outpatient department of Thoracic medicine, Rajiv Gandhi Government General 
Hospital, were explained about the study purpose, procedure and benefits of the 
study. Information sheet and informed consent forms written in the regional 
language were provided to each patient. After obtaining written informed consent 
in patient's own language, the study was carried out.  
 
SCREENING 
The demographic details of the patients were recorded. The subjects were 
screened by complete medical history, clinical examination and laboratory 
investigations.  
 
RECRUITMENT 
After screening those who fulfilled the inclusion and exclusion criteria 
were enrolled in the study. 
 
RANDOMIZATION: 
The enrolled patients were randomized by simple randomization into either 
control group or study group and received the respective therapy. 
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TREATMENT PLAN 
STANDARD TREATMENT 
 MDI containing Budesonide 200 mcg and Formoterol 6 mcg bid  
 
CONTROL GROUP 
 Standard treatment 
 
TEST GROUP                     
 Standard treatment + Tablet cholecalciferol 1000 IU/day for 12 weeks. 
 
 The study medication was issued for 2 weeks. After assessing the 
compliance at the end of 2 weeks, study   medication was issued for the 
subsequent 2 weeks. The same procedure was followed till the completion of 
study.  
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STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
ENROLLMENT 
RANDOMIZATION 
STUDY GROUP 
30 patients 
CONTROL GROUP 
30 patients 
Standard Therapy   Standard Therapy + Tab. 
Cholecalciferol 1000 IU OD 
TREATMENT PERIOD – 12 WEEKS 
FOLLOW UP PERIOD – 4 WEEKS   
SCREENING 
Complete medical history, 
clinical examination, 
biochemical investigations.  
60 PATIENTS COMPLETED 
STUDY 
STATISTICAL ANALYSIS 
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INVESTIGATIONS: 
Baseline investigations:  
 Complete blood count- Hb, TC, DC, ESR, Eosinophil count 
  Renal function test 
 Random blood sugar 
 Routine urine analysis 
  Vitamin D levels  
All the baseline investigations were done at screening and at the end of 12th week 
of the study. 
 
Pulmonary function tests – FEV1, FVC, PEFR were done at baseline, 6th and 
12thweek. 
 
STUDY VISITS 
SCREENING/ BASELINE VISIT: 
 Written informed consent obtained. 
 Demographic details obtained. 
 Medical history taken and recorded. 
 Vital signs recorded. 
 General, Systemic examination done. 
 Laboratory investigations 
 Complete blood count- Hb, TC, DC, ESR, Eosinophil count 
  Renal function test 
 Random blood sugar 
72 
 
 Routine urine analysis 
  Vitamin D levels 
 Pulmonary function tests – FEV1, FVC, PEFR done 
 
VISIT 1 (Baseline): 
 Investigation reports collected. 
 Randomization done. 
 Vital signs recorded. 
 Pulmonary function tests done. 
 Study drugs were issued for 2 weeks to respective groups. 
 Instructed to return the empty strips during subsequent visit. 
 Patients were instructed to report if any adverse events occur. 
 
VISIT 2 (end of 2 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Patients were asked to return empty strips to check compliance. 
 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 3 (end of 4 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Patients were asked to return empty strips to check compliance. 
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 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 4 (end of 6 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Pulmonary function tests done. 
 Patients were asked to return empty strips to check compliance. 
 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 5 (end of 8 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Patients were asked to return empty strips to check compliance. 
 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
 
VISIT 6 (end of 10 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Patients were asked to return empty strips to check compliance. 
 Adverse events monitored. 
 Study medication issued for subsequent 2 weeks. 
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VISIT 7 (end of 12 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Pulmonary function tests done. 
 Patients were asked to return empty strips to check compliance. 
 Adverse events monitored. 
 
VISIT 8 (end of 16 weeks) 
 Vital signs recorded. 
 General, Systemic examination done. 
 Adverse events monitored. 
 
ASSESSMENT 
Pulmonary function tests 
 FEV1- 
 FVC 
 PEFR 
 
INSTRUCTIONS TO PATIENTS 
 Patients were instructed clearly regarding the regular intake of the 
medicines. They were advised to report to the OPD for assessment and for 
receiving the drugs. They were counselled to report if any adverse reaction occurs. 
 
COMPLIANCE 
Patient compliance was monitored by daily drug reminder chart. 
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FOLLOW UP: 
The patients were further followed up for a post treatment period of 4 
weeks. After the completion of 16 weeks of study period, the patients were 
provided appropriate care at Institute of Thoracic medicine, Rajiv Gandhi 
Government General Hospital, Chennai. 
 
ADVERSE EVENTS: 
Any adverse event reported by the patient or observed by the investigator 
during the study was recorded. The onset of adverse event, causal relationship to 
the study drug and action taken was recorded. Appropriate medical care was 
provided. 
 
WITHDRAWAL: 
During the study period the subject was allowed to withdraw his/her 
voluntary consent and opt out of study. Similarly, at the discretion of the 
investigator, the subjects were withdrawn from the study if any serious adverse 
event was reported by the patient or observed by the investigator. 
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STATISTICAL ANALYSIS: 
 The obtained data was analysed statistically. 
 
 Distribution of age was analysed using student’s t-test and sex distribution 
was analysed by Pearson chi- square test. 
 
 The biochemical investigations were performed at baseline and at the end 
of 12 weeks. The differences within the groups before and after treatment were 
analysed using student’s paired t- test. 
 
The difference within the groups in FEV 1, FVC, PEFR was analysed 
using students paired t-test. Similarly, the difference between the control and test 
groups was analysed using independent t test. 
 
Statistical analysis was done by using SPSS software version 21. p value 
<0.05 was considered to be statistically significant. 
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RESULTS 
 
This study was conducted to evaluate the efficacy and safety of Cholecalciferol as 
an add on therapy to standard treatment in adult patients with bronchial asthma. 
 
 107 patients were screened. 
 41 patients were excluded from the study based on exclusion criteria. 
 6 patients who were eligible were not willing to participate in the study. 
 60 patients were enrolled in this study.   
 All the enrolled patients completed the study. 
 There were no drop outs. 
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TABLE 1: AGE DISTRIBUTION 
AGE IN 
YEARS 
CONTROL GROUP STUDY GROUP 
NO PERCENTAGE NO PERCENTAGE 
25-40 11 36.66% 10 33.33% 
41-55 14 46.66% 15 50% 
56-70 5 16.66% 5 16.66% 
TOTAL 30 100% 30 100% 
 
Table 1 shows age distribution of both the groups. 
Age group 41-55 years had most number of patients in both the groups followed 
by age group 25-40 years. 
 
FIGURE 1: AGE DISTRIBUTION 
 
Figure 1 is the graphical representation of table 1. 
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TABLE 2: MEAN AGE DISTRIBUTION 
GROUP NO OF PATIENTS 
MEAN AGE in 
years SD 
CONTROL 30 43.85 10.10 
STUDY 30 44.96 9.32 
p Value 0.6599 
 
Table 2 shows the mean age distribution of both the groups.  
Mean age was similar in both the groups. 
There were no statistically significant differences between the groups. 
 
FIGURE 2: MEAN AGE DISTRIBUTION 
 
 
 
Figure 2 is the graphical representation of Table 2. 
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TABLE 3: SEX DISTRIBUTION 
 
CONTROL GROUP STUDY GROUP 
NO OF 
PATIENTS PERCENTAGE 
NO OF 
PATIENTS PERCENTAGE 
MALE 17 56.66 14 46.66 
FEMALE 13 43.33 16 53.33 
TOTAL 30 100 30 100 
p VALUE 0.4383 
 
Table 3 shows the sex distribution in both the groups. 
Control group had 56.6% males and 43.3% females while study group had 46.6% 
males and 53.3% females. There was no significant difference in male and female 
distribution in both the groups (p value=0.4383). 
 
FIGURE 3: SEX DISTRIBUTION 
 
Figure 3 is the graphical representation of Table 3. 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
CONTROL STUDY
SEX DISTRIBUTION
MALE FEMALE
81 
 
TABLE 4: MEAN DURATION OF ILLNESS 
GROUP MEAN DURATION OF ILLNESS (IN YEARS) 
CONTROL 9 
STUDY 8.33 
 
Table 4 shows the mean duration of asthma in control and study group. 
 
FIGURE 4: MEAN DURATION OF ILLNESS 
 
 
 
Figure 4 is the graphical representation of Table 4. 
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TABLE 5: Forced Expiratory Volume in 1 second (FEV 1) 
GROUP BASELINE MEAN±SD 
6 WEEKS 
MEAN±SD 
12 WEEKS 
MEAN±SD p Value 
CONTROL 62.94±1.66 66.05±2.67 70.25±2.24 0.0001 
STUDY 63.60±2.05 67.17±2.75 72.44±1.97 0.0001 
p Value 0.1815 0.1149 0.0109  
 
Table 5 shows the improvement in percentage predicted Forced Expiratory 
Volume in 1 second(FEV1) in control and study group. 
Within group analysis showed significant improvement in FEV1 in both groups at 
12 weeks compared to baseline (p value=0.0001). 
Between the groups analysis showed a significant difference at the end of 12 
weeks p value=0.0109. 
 
FIGURE 5: Forced Expiratory Volume in 1 second (FEV 1) 
 
Figure 5 is the graphical representation of Table 5. 
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TABLE 6: Forced Vital Capacity (FVC) 
GROUP BASELINE MEAN±SD 
6 WEEKS 
MEAN±SD 
12 WEEKS 
MEAN±SD p Value 
CONTROL 63.87±1.68 67.16±1.96 69.27±1.83 0.0001 
STUDY 64.35±2.04 68.11±2.22 71.34±3.97 0.0001 
p value 0.3339 0.0842 0.0120  
 
Table 6 shows the improvement in percentage predicted Forced Vital 
Capacity(FVC) in control and study group. 
Within group analysis showed significant improvement in FVC in both groups at 
12 weeks compared to baseline (p value=0.0001). 
Between the groups analysis showed a significant difference at the end of 12 
weeks p value=0.0120. 
 
FIGURE 6: Forced Vital Capacity (FVC) 
 
 
Figure 6 is the graphical representation of Table 6. 
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TABLE 7: Peak Expiratory Flow Rate (PEFR) 
GROUP BASELINE MEAN±SD 
6 WEEKS 
MEAN±SD 
12 WEEKS 
MEAN±SD p Value 
CONTROL 65.66±1.80 69.21±1.7 73.45±2.44 0.0001 
STUDY 66.10±1.73 70.40±3.33 75.16±3.14 0.0001 
p Value 0.3381 0.0866 0.0219  
 
Table 7 shows the improvement in percentage predicted Peak Expiratory Flow 
Rate(PEFR) in control and study group. 
Within group analysis showed significant improvement in PEFR in both groups at 
12 weeks compared to baseline (p value=0.0001). 
Between the groups analysis showed a significant difference at the end of 12 
weeks p value=0.0219. 
 
FIGURE 7: Peak Expiratory Flow Rate (PEFR) 
 
Figure 7 is the graphical representation of Table 7. 
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TABLE 8: Asthma Control Questionnaire Score 
GROUP BASELINE MEAN±SD 
12 WEEKS 
MEAN±SD p Value 
CONTROL 2.25±1.21 4.99±1.29 0.0001 
STUDY 2.48±1.23 5.24±1.01 0.0001 
p Value 0.4812 0.3975  
 
Table 8 shows the Asthma Control Questionnaire score in control and study 
group. 
 
FIGURE 8: ACQ 
 
 
Figure 8 is the graphical representation of Table 8. 
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TABLE 9: NUMBER OF EXACERBATIONS 
 CONTROL GROUP STUDY GROUP 
NO OF 
EXACERBATIONS 7(23.33%) 3(10%) 
 
Table 9 shows the number of exacerbations in patients of both the groups. 
7 patients had exacerbations in control group and 3 patients had exacerbations in 
study group. 
 
FIGURE 9: NUMBER OF EXACERBATIONS  
 
Figure 9 is the graphical representation of Table 9. 
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BIOCHEMICAL INVESTIGATIONS 
 
TABLE 10: CONTROL GROUP 
INVESTIGATION BASELINE 12 WEEKS p VALUE 
RANDOM BLOOD 
SUGAR 98.87±9.68 96.67±9.94 0.7948 
UREA 27.33±4.05 26.1±3.9 0.2602 
CREATININE 0.89±0.2 0.92±0.21 0.5609 
ABSOLUTE 
EOSINOPHIL COUNT 401±49.62 380.63±50.55 0.1226 
 
Table 10 shows the biochemical parameters of control group. 
Statistical analysis within the group did not show any significant difference in 
random blood sugar, urea, creatinine and absolute eosinophil count.  
 
TABLE 11: STUDY GROUP 
INVESTIGATION BASELINE 12 WEEKS p VALUE 
RANDOM BLOOD 
SUGAR 97.03±9.81 98.83±9.91 0.5380 
UREA 26.5±4.44 25.07±3.69 0.1586 
CREATININE 0.94±0.3 0.85±0.25 0.2017 
ABSOLUTE 
EOSINOPHIL COUNT 402.91±48.73 385.57±46.99 0.1631 
 
Table 11 shows the biochemical parameters of study group.  
Statistical analysis within the group did not show any significant difference in 
random blood sugar, urea, creatinine and absolute eosinophil count.  
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TABLE 12: SERUM VITAMIN D 
GROUP BASELINE 12 WEEKS p Value 
CONTROL 22.83±4.79 24.63±6.41 0.1563 
STUDY 25.27±4.91 55.97±20.41 0.0001 
 
Table 12 shows serum vitamin D levels in control and test group. 
Study group showed a statistically significant improvement in serum vitamin D 
levels at 12 weeks compared to control group. 
 
TABLE 13: INCIDENCE OF ADVERSE DRUG REACTIONS 
 CONTROL GROUP STUDY GROUP 
NO OF ADRs 16(53.33%) 14(46.66%) 
 
Table 13 shows the incidence of ADRs in patients of both the groups. 
16 ADRs were reported in control group and 14 ADR were reported in study 
group. 
 
FIGURE 10: INCIDENCE OF ADVERSE DRUG REACTIONS 
 
Figure 10 is the graphical representation of Table 13. 
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TABLE 14: ADVERSE DRUG REACTIONS MONITORING 
ADR CONTROL GROUP STUDY GROUP 
TREMOR 2 3 
INSOMNIA 1 2 
NAUSEA - 2 
GASTRITIS 4 1 
PALPITATION 2 2 
SLEEP DISTURBANCE 2 1 
ORAL CANDIDIASIS 3 1 
MYALGIA 2 2 
 
Table 14 shows the adverse effect profile of both the groups. 
Adverse effects were reported more in control group than in study group. Tremor 
and gastritis were the most common ADRs. 
FIGURE 11: ADVERSE DRUG REACTIONS MONITORING 
 
Figure 11 is the graphical representation of Table 14. 
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TABLE 15: CAUSALITY ASSESSMENT OF ADVERSE DRUG 
REACTIONS- CONTROL GROUP 
ADR Certain Probable Possible Un-likely 
Un-
classified 
Un-
classifiable 
TREMOR   2    
INSOMNIA   1    
NAUSEA   -    
GASTRITIS   4    
PALPITATION   2    
SLEEP 
DISTURBANCE   2    
ORAL 
CANDIDIASIS   3    
MYALGIA   2    
 
Table 15 shows causality assessment of individual ADR in control group. 
Causality assessment was done using WHO-UMC causality assessment scale. 
ADRs were categorized as possible. 
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TABLE 16: CAUSALITY ASSESSMENT OF ADVERSE DRUG 
REACTIONS-STUDY GROUP 
ADR Certain Probable Possible Un-likely 
Un-
classified 
Un-
classifiable 
TREMOR   3    
INSOMNIA   2    
NAUSEA   2    
GASTRITIS   1    
PALPITATION   2    
SLEEP 
DISTURBANCE   1    
ORAL 
CANDIDIASIS   1    
MYALGIA   2    
 
Table 16 shows causality assessment of individual ADR in control group. 
Causality assessment was done using WHO-UMC causality assessment scale. 
ADRs were categorized as possible. 
 
TABLE 17: SEVERITY ASSESSMENT OF ADVERSE DRUG 
REACTIONS BY MODIFIED HARTWIG SIEGEL SCALE 
SEVERITY CONTROL GROUP STUDY GROUP 
MILD 16 14 
MODERATE - - 
SEVERE - - 
 
Table 17 shows severity assessment of ADR by modified Hartwig Siegel scale. 
All the ADR in control and study group were mild in severity. 
 
Discussion 
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DISCUSSION 
 
 Bronchial asthma is a chronic inflammatory disease of the airways 
characterized by episodic airflow obstruction and airway hyperresponsiveness. 
Asthma is a heterogenous clinical syndrome with wide variability in pathologic, 
clinical and physiologic parameters among different patients.(2) 
 
 Asthma is a highly prevalent disease affecting nearly 300 million people 
worldwide. The recent rising trend in prevalence of asthma in India is attributed to 
various factors like industrialization, air pollution, life style changes, etc. Asthma 
is a disease with severe morbidity affecting the patient’s day to day activities in 
multiple ways, however death due to asthma is rather uncommon.(1) 
 
 The pathogenesis of Bronchial asthma shows an interplay between various 
environmental and endogenous factors which act as risk factors, precipitants of 
asthma such as atopy, genetic predisposition, respiratory infections, airway 
irritants, drugs, smoking, etc.(1,2) 
 
 The pathogenesis of asthma is very complex and involves a variety of cells 
and numerous mediators such as cytokines, chemokines, leukotrienes, 
prostanoids, etc which serve to initiate, perpetuate and coordinate the multiple 
processes seen in the inflammation. Inflammation in the airways is the major 
pathologic abnormality seen in asthma and is also responsible for the airway 
dysfunction.(2,3) 
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 The repeated cycles of inflammation lead to chronic inflammation of the 
airways characterized by epithelial damage, subepithelial fibrosis, airway smooth 
muscle hypertrophy and hyperplasia, mucous gland hyperplasia which impair the 
normal respiratory function.(3) 
 
 Asthmatic patients commonly present with symptoms of breathlessness, 
chest tightness, cough, sputum production. Pulmonary function tests help in the 
diagnosis as well as monitoring patient’s response to treatment.(5) 
 
 Management of bronchial asthma involves assessing and monitoring 
asthma severity and control, patient education, control of environmental factors 
that influence asthma and use of pharmacologic agents.(5) 
 
 Various pharmacological agents used to treat bronchial asthma are 
classified into two major types- bronchodilators and anti-inflammatory agents. 
Bronchodilators include beta 2 agonists, anticholinergics and methylxanthines. 
These are mainly used as reliever (rescue) medications. These agents act 
principally by relaxation of bronchial smooth muscle and thereby reversing the 
airflow obstruction. Anti-inflammatory agents include corticosteroids, leukotriene 
antagonists and anti IgE therapy. These are mainly used as chronic controllers. 
These agents reduce airway inflammation and helps to maintain control over 
asthma. However, the chronic use of corticosteroids which forms the backbone of 
asthma pharmacotherapy is associated with various adverse effects both locally 
and systemically like dysphonia, oral candidiasis, weight gain, osteoporosis, 
hypertension, etc and there is a variability in patient’s response to 
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corticosteroids.(29) Therefore, there is a dire need for newer agents that reduce 
airway inflammation and improve long term control over asthma. 
 
 Cholecalciferol or vitamin D is a fat-soluble vitamin synthesized from 7-
dehydrocholesterol in the skin by the action of UV-B rays from sun. However, 
cholecalciferol is not active as such and it is converted to its metabolically active 
form 1,25 dihydroxy cholecalciferol in kidney.(6) 
 
 In various target cells, 1,25 dihydroxy cholecalciferol binds to vitamin D 
receptor and the vitamin D receptor complex binds to specific DNA sequences 
resulting in changes in transcription of various genes and thereby leading to 
various changes in cellular function. In addition to its well-established role in 
calcium and phosphate homeostasis, bone modelling and remodelling, 
cholecalciferol also has a role in immune system, skin, skeletal muscles, etc.(6) 
 
 Several studies have shown a beneficial role of vitamin D in bronchial 
asthma. Vitamin D deficiency is more common in asthmatics compared to general 
population. Low level of vitamin D has multiple deleterious effects on bronchial 
asthma like frequent exacerbations; increased airway hyperresponsiveness; 
reduction FEV1, FVC and increased requirement of corticosteroids.(7,8,35,38) 
 
 Vitamin D improves long term control over bronchial asthma by reducing 
the production of proinflammatory cytokines, increasing the production of anti-
inflammatory cytokines, inhibiting proliferation and differentiation of various 
cells involved in asthma, inhibiting proliferation of airway smooth muscle cells, 
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enhancing the anti-inflammatory actions of corticosteroids, improving pulmonary 
immune function. Thus, vitamin D by its anti-inflammatory actions inhibits 
chronic inflammation and airway remodelling thereby resulting in improved 
control over bronchial asthma.(7,9-10,33,35-56) 
 
 In this study 107 patients were screened, and 60 patients who fulfilled the 
eligibility criteria were enrolled. They were randomised into control and study 
group of 30 patients each. The patients in the control group received standard 
treatment comprising formoterol and budesonide MDI and study group received 
tablet cholecalciferol 1000 IU/day in addition to standard treatment for 12 weeks. 
 
 The mean age in the control and study group was 43.85 years and 44.96 
years respectively. There was no significant difference in the number of male and 
female participants between the groups. 
 
 At the end of 12 weeks FEV1 showed a significant improvement in control 
group by 11.6% and in study group by 13.9%. On comparing both the groups 
there was a statistically significant improvement in the study group compared to 
the control group with p value of 0.0109. 
 
 FVC showed a significant improvement of 8.45% in control group and 
10.86% in study group at the end of 12 weeks study period. On comparing there 
was a statistically significant improvement in the study group compared to the 
control group with p value of 0.0120. 
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  At the end of 12 weeks PEFR showed a significant improvement by 
11.86% in control group and 13.70% in study group. Between the groups analysis 
showed a statistically significant improvement in the study group compared to the 
control group with p value of 0.0219.  
 
Number of exacerbations in the study period were 3 in study group 
compared to 7 in control group. Asthma Control Questionnaire scores showed a 
significant improvement of 2.74 points and 2.76 points at the end of 12 weeks in 
control and study group respectively. 
 
Serum vitamin D levels showed a significant improvement in study group 
by 1.2 times compared to 0.08 times in control group. This is statistically 
significant improvement with p value of 0.001. 
 
 The is consistent with previous studies done by Yadav et al, Arshi et al, 
Nageswari et al.(35,50,51) 
 
Assessment of asthma control using asthma control questionnaire showed a 
significant improvement at the end of 12 weeks in both the groups. 
 
 Addition of cholecalciferol did not affect blood pressure and other 
biochemical parameters like urea, creatinine, RBS. 
 
 The incidence of adverse effects was 46.6% in the study group and 53.3% 
in the control group. Tremor and headache were the commonest adverse event. 
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 The number of adverse events were less in patients receiving 
cholecalciferol compared to patients receiving standard therapy. All the adverse 
drug reactions were categorized as possible under WHO-UMC causality 
assessment scale. According to modified Hartwig and Siegel severity assessment 
scale all the reactions reported were mild. This shows that cholecalciferol did not 
increase the occurrence of adverse events. 
 
 As evidenced by earlier studies, this study has also showed that addition of 
cholecalciferol to standard therapy significantly improved long term control over 
asthma. 
  
Conclusion 
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CONCLUSION 
 
From our study, we conclude that in patients with bronchial asthma 
1. Cholecalciferol as an add on therapy is effective in improving FEV1, FVC 
and PEFR thereby Cholecalciferol improves long term control over asthma. 
2. Dose escalation of corticosteroids was not required. 
3. Cholecalciferol was well tolerated.  
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Appendices 
APPENDIX-1 
LIST OF ABBREVIATIONS 
ACQ  - Asthma Control Questionnaire 
ACT  - Asthma Control Test 
AD  - Anno Domini 
ADR  - Adverse Drug Reaction 
AHR  - Airway Hyper-responsiveness 
AMP  - Adenosine Mono Phosphate 
ATAQ - Asthma Therapy Assessment Questionnaire 
DC  - Differential Count 
DNA  - Deoxyribo Nucleic Acid 
ECG  - Electrocardiogram 
ESR  - Erythrocyte Sedimentation Rate 
FEV1  - Forced Expiratory Volume in one second 
FGF  - Fibroblast Growth Factor 
FVC  - Forced Vital Capacity 
GCP  - Good Clinical Practise 
GM-CSF - Granulocyte Monocyte Colony Stimulating Factor 
HLA  - Human Leukocyte Antigen 
ICS  - Inhaled Corticosteroid 
IFN  -  Interferon 
IgE  - Immunoglobulin E 
IL  -  Interleukin 
IU  - International Units 
LABA - Long Acting Beta Agonist 
LAMA- Long Acting Muscarinic Antagonist 
LT- Leukotriene 
MAP- Mitogen Activated Kinase 
MDI- Metered Dose Inhaler 
OD- Once Daily 
OPD- Out Patient Department 
PAF- Platelet Activating Factor 
PDGF- Platelet Derived Growth Factor 
PEFR- Peak Expiratory Flow Rate 
PKA- Protein Kinase A 
PKC- Protein Kinase C 
PTH- Para Thyroid Hormone 
RBS- Random Blood Sugar 
RGGGH- Rajiv Gandhi Government General Hospital 
RXR- Retinoid X Receptor 
SABA- Short Acting Beta Agonists 
SAMA- Short Acting Muscarinic Antagonists 
SD- Standard Deviation 
TC- Total Count 
TH- T Helper 
TNF- Tumour Necrosis Factor 
TSLP- Thymic Stromal Lympho Protein 
UMC- Uppsala Monitoring Centre 
UV- Ultraviolet 
VDR- Vitamin D Receptor 
VDRE- Vitamin D Responsive Element 
VEGF- Vascular Endothelial Growth Factor 
VIP  -  Vasoactive Intestinal Peptide 
WHO- World Health Organization 
  
APPENDIX-2 
CASE REPORT FORM 
 
 
NAME:  Mr/Mrs                                                 AGE/SEX:                          
OP No:                                                                 DIAGNOSIS:   
ADDRESS:                                                                 CONTACT NO.: 
 
 
VISIT 1 (DAY 1) 
 
 
PAST HISTORY: 
 
 
ALLERGIC TO: 
                                                                                                                                                                                                     
 
PERSONAL HISTORY: 
 
 
CLINICAL EXAMINATION: 
 
Ht:  Wt:  
 
VITAL SIGNS  
             Pulse rate:                               BP:           
  
 
SYSTEMIC EXAMINATION 
 
RS - 
CVS - 
ABDOMEN – 
CNS - 
 
LAB INVESTIGATIONS: 
 
Complete Blood Count:    
Hb:  TC:  DC: P    L    E    M    B           ESR: 
Fasting Blood sugar: mg/dl. Blood urea: mg/dl.  Serum Creatinine: mg/dl. 
Liver function tests:  SGOT:  IU/L   SGPT:         IU/L 
Routine urine analysis:    sugar  albumin deposits 
Pulmonary function tests:   FEV1:                                  FVC: 
PEFR: 
                                                                                                                                  
TREATMENT: 
 
VISIT 2 (6th  week)  
  
CLINICAL EXAMINATION: 
 
VITAL SIGNS  
             Pulse rate:                               BP:      
Adverse events: 
 
VISIT 3 (12th week) 
CLINICAL EXAMINATION: 
 
VITAL SIGNS  
             Pulse rate:                               BP:      
Adverse events: 
 
VISIT 4 (16th week) 
CLINICAL EXAMINATION: 
 
VITAL SIGNS  
             Pulse rate:                               BP:      
Adverse events: 
 
 
 
 
 
 
 
Parameters 
VISIT 1 
(Day 1) 
VISIT 2 
(6th  week) 
VISIT 3 
(12th  week) 
VISIT 4 
(16th week) 
FEV1     
FVC     
PEFR     
Serum Vitamin 
D3     
 
Adverse events 
    
 
Date & Sign 
    
 
 
Name of the Doctor:       Date: 
Signature:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX-3 
INFORMED CONSENT FORM 
Title:  “A Prospective, Randomized, Open label, Comparative study of 
Cholecalciferol as an add on therapy to standard treatment in adult patients with 
bronchial asthma” 
Name of the Participant: 
I                                            have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 years of 
age and, exercising my free power of choice, hereby give my consent to be included as a 
participant in this study. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital. 
6. I hereby give permission to the investigators to release the information obtained 
from me as a result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies, and IEC.  
7. I understand that my identity will be kept confidential if my data are publicly 
presented. 
8.  I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form, I attest that the information given in this document has 
been clearly explained to me and understood by me, I will be given a copy of this 
consent document. 
1. Name and signature / thumb impression of the participant (or legal representative 
if participant incompetent) 
Name ____________________Signature _______________Date____________ 
2. Name and signature of impartial witness (required for illiterate patients) 
Name ____________________Signature _______________Date____________ 
Address and contact number of the impartial witness: 
3. Name and signature of the investigator or his representative obtaining consent: 
Name ____________________Signature _______________Date____________ 
 
 APPENDIX-4 
INFORMATION TO PARTICIPANTS 
 
Title: “A Prospective, Randomized, Open label, Comparative study of 
Cholecalciferol as an add on therapy to standard treatment in adult patients with 
bronchial asthma” 
 
Principal Investigator:  
 
Name of Participant: 
 
This study is being conducted in Thoracic medicine OPD at Rajiv Gandhi Govt. General 
Hospital, Chennai. You are invited to take part in this study. The information in this 
document is meant to help you decide whether or not to take part. Please feel free to ask if 
you have any queries or concerns. 
 
What is the purpose of this study? 
 
Bronchial asthma is a chronic disease characterized by airway hyper 
responsiveness and reversible airflow obstruction leading to repeated episodes of 
wheezing, chest tightness and cough. This leads to airway remodeling resulting in 
irreversible airway obstruction. It is one of the most common chronic diseases globally. 
Its prevalence is raising in developing countries owing to factors like urbanization, 
industrialization, environmental pollution, changes in lifestyle, etc.  
Vitamin D3 reduces airway hyper responsiveness and inhibits airway remodeling. 
Vitamin D3 improves the response to inhaled and oral corticosteroids. We want to test 
the efficacy and safety of treatment with Vitamin D3 in reducing severity of bronchial 
asthma. 
We have obtained permission from the Institutional Ethics Committee.  
 
  
The study design: 
 
All patients in the study will be divided into 2 groups A & B. You will be assigned to 
either of the groups. Group A will receive standard treatment & Group B will receive 
standard treatment + Vitamin D3. 
 
Study Procedures: 
 
The study involves evaluation of severity of bronchial asthma. The planned scheduled 
visits involve visits at 6th, 12th ,16th week after your initial visit. You will be required to 
visit the hospital 3 times during the study. At each visit, the study physician will examine 
you. Blood tests will be carried out twice during the study (at screening and at the end of 
study) and total of about 40 ml blood will be collected. These tests are essential to 
monitor your condition, and to assess the safety and efficacy of the treatment given to 
you. 
In addition, if you notice any adverse events, you have to report it. You will be required 
to return unused study medicines when you report for your scheduled visits. This will 
enable correct assessment of the study results. 
 
Possible benefits to you – Vitamin D3 along with standard treatment will cause 
reduction in severity of bronchial asthma. 
 
 Possible benefits to other people - The results of the research may provide benefits to 
the society in terms of advancement of medical knowledge and/or therapeutic benefit to 
future patients.  
 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical 
history). By signing this document, you will be allowing the research team investigators, 
other study personnel, and Institutional Ethics Committee to view your data, if required. 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or 
your relationship with the investigator or the institution. You will be taken care of and 
you will not lose any benefits to which you are entitled.  
 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw 
from this study at any time during the course of the study without giving any reasons. 
However, it is advisable that you talk to the research team prior to stopping the 
treatment/discontinuing of procedures etc. 
The expenditure for the treatment and investigation for this study will not be collected 
from you. 
 
 
Signature of Investigator                                                     Signature of Participant   
 
Date                                                                                          Date   
 
 
 
   
APPENDIX-5 
ASTHMA CONTROL QUESTIONNAIRE 
 
Please answer questions 1-6. Circle the number of the response that best describes how 
you have been in the past week. 
1. On average during the past week, how often were you woken by your asthma 
during the night? 
a. Never 
b. Hardly ever 
c. A few times 
d. Several times 
e. Many times 
f. A great many times 
g. Unable to sleep because of asthma 
 
2. On average, during the past week, how bad are your asthma symptoms when you 
wake up in the morning? 
a. No symptoms 
b. Very mild symptoms 
c. Mild symptoms 
d. Moderate symptoms 
e. Quite severe symptoms 
f. Severe symptoms 
g. Very severe symptoms 
 
3. In general, during the past week, how limited were you in your activities because 
of your asthma? 
a. Not limited at all 
b. Very slightly limited 
c. Slightly limited 
d. Moderately limited 
e. Very limited 
f. Extremely limited 
g. Totally limited 
 
4. In general, during the past week, how much shortness of breath did you 
experience of your asthma? 
a. None 
b. A very little 
c. A little 
d. A moderate amount 
e. Quite a lot 
f. A great deal 
g. A very great deal 
 
5. In general, during the past week, how much time did you wheeze? 
a. Not at all 
b. Hardly any of the time 
c. A little of the time 
d. A moderate amount of the time 
e. A lot of the time 
f. Most of the time 
g. All the time 
 
6. On average, during the past week, how many puffs/inhalations of short-acting 
bronchodilator (eg. Ventolin) have you used each day? 
a. None 
b. 1-2 puffs/inhalations most days 
c. 3-4 puffs/inhalations most days 
d. 5-8 puffs/inhalations most days 
e. 9-12 puffs/inhalations most days 
f. 13-16 puffs/inhalations most days 
g. More than 16 puffs/inhalations most days 
 
7. FEV1% predicted: 
a. >95% predicted 
b. 90-95% predicted 
c. 80-89% predicted 
d. 70-79% predicted 
e. 60-69% predicted 
f. 50-59% predicted 
g. <50% predicted 
Scoring: 
Sum points from all questions 1-7. Divide this sum by 7. 
ACQ score = _________________ 
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